Dr Waldman discussed social media as a patient education tool, the unforeseen benefits on clinical practice by using TikTok, ...

Ivarmacitinib use for 52 weeks in adolescents and adults with AD was associated with skin clearance, symptom relief, and quality of life improvements.

Patients with psoriasis with obesity are at an increased risk for primary failure of biologic therapies when compared with those without obesity.

Apremilast is effective for the treatment of patients with plaque psoriasis who have limited skin involvement, including in high-impact areas.

No significant differences were noted in efficacy outcomes associated with upadacitinib vs abrocitinib at 12 weeks of treatment for AD.

The quadrivalent HPV vaccine provides durable immune responses and protects against cervical disease in women with HIV.

Real-world data from Fall Clinical 2026 reveal widespread treatment dissatisfaction, anxiety, and steroid hesitancy among ...

Adalimumab use among patients with HS was associated with a greater risk of developing psoriasis and psoriatic arthritis through 1 year.

Michelle Min, MD, MS, reviewed best practices for managing cutaneous lupus and discussed emerging therapies practitioners ...

Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...

State health officials fighting measles outbreaks asked the CDC for help getting a faster test, but the CDC couldn’t help after 2 months.

Pediatric-onset psoriasis was associated with greater response to IL-17 inhibitor treatment when compared with adult-onset psoriasis.